DCN Dx Bolsters Board with Appointment of Former Meridian Biosciences CEO Jack Kenny

CARLSBAD, Calif., March 12, 2024 /PRNewswire/ -- DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, announces the appointment of industry veteran Jack Kenny to its board of directors. With more than 30 years of experience in operational and commercial leadership in healthcare and medical device sectors, Kenny is set to bring invaluable expertise to the DCN Dx board.

Kenny currently serves as an independent director for Quantum Si and as Chairman of the Board at Biomerica. His previous role as Chief Executive Officer of Meridian Bioscience was marked by a significant turnaround, leading to the company's acquisition by SJL Partners and SD Biosensor for approximately $1.53 billion in January 2023.

Upon his appointment to DCN Dx's board, Kenny said, "During my time at Meridian, we collaborated closely with the DCN Dx team. I was impressed by their commitment to quality and innovation. I look forward to contributing to DCN Dx's growth and enhancing its role as a key partner in the diagnostics industry."

"Jack's extensive experience and leadership in the healthcare sector make him a perfect fit for our strategic vision," said Charlie Mamrak, DCN Dx's CEO. "His insights into the diagnostics landscape will be invaluable as we continue to expand our capabilities and impact."

Kenny's prior roles include Senior Vice President and General Manager, North America at Siemens Healthcare, and Vice President and General Manager, U.S. Region for Becton Dickinson's Diagnostic Systems, among others. His breadth of experience across different segments of the healthcare industry will provide DCN Dx with a unique perspective on business growth and operational excellence.

About DCN Dx

DCN Dx, based in Carlsbad, California, is a global leader in IVD CDMO and CRO services. Our multidisciplinary team specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays.

Our personalized approach to IVD product development has supported more than 560 programs from over 260 clients. We can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, our clinical research expertise extends to a wide range of IVD devices, all with a focus on innovation, usability, and performance.

With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.

For more information contact:
Mitzi Rettinger
Chief Revenue Officer, DCN Dx
Main: (760) 804-3886
Mobile: (512) 431-5836
[email protected]

SOURCE DCN Dx